G1 Therapeutics, an oncology therapy developer spun out of North Carolina University. has filed for a $115m initial public offering that will provide an exit for MedImmune, a subsidiary of pharmaceutical firm AstraZeneca.
SUBSCRIBE
Biohealth Innovation
Founding Member of
